-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651 Anatomical Predictors of Venous Thromboembolism Recurrence after Isolated Superficial Vein Thrombosis

Pathophysiology of Thrombosis
Program: Oral and Poster Abstracts
Type: Oral
Session: 331. Pathophysiology of Thrombosis: Prediction of VTE and Complications
Monday, December 7, 2015: 3:15 PM
W311ABCD, Level 3 (Orange County Convention Center)

Jean-Philippe Galanaud, MD, PhD1*, Marie-Antoinette Sevestre, MD, PhD2*, Céline Genty, MsC3*, Susan R Kahn, MD, MSc4,5, Gilles Pernod, MD, PhD6*, Dominique Brisot, MD7*, Isabelle Quéré, MD, PhD1* and Jean-Luc Bosson, MD, PhD3*

1Department of Internal Medicine, Montpellier University Hospital, Montpellier, France
2Vascular Medicine, Amiens University Hospital, Amiens, France
3Clinical Investigation Center, Grenoble University Hospital, Grenoble, France
4Division of Internal Medicine and Department of Medicine, McGill University, Montreal, QC, Canada
5Center for Clinical Epidemiology, McGill University, Jewish General Hospital, Montreal, QC, Canada
6Department of Vascular Medicine, University Hospital Grenoble, Grenoble, France
7Vascular Medicine Office, Clapiers, France

Background: Isolated superficial vein thrombosis (iSVT) (i.e. without concurrent deep-vein thrombosis or pulmonary embolism) is a frequent event. Its clinical significance and management are controversial. Data on long-term follow-up are scarce and the impact of anatomical characteristics of iSVT on the risk of venous thromboembolism (VTE) (DVT and/or PE) recurrence has not been assessed.

Objective: To determine the impact of anatomical characteristics of iSVT on the long-term risk of VTE recurrence.

Methods: Using data from the The OPTIMEV (OPTimisation de l’Interrogatoire dans l’_evaluation du risque throMbo-Embolique Veineux) study, a prospective, observational, multicenter study, we assessed at 3 years in patients recruited for an objectively confirmed iSVT i) cumulative rates of DVT, PE and SVT recurrences using the Kaplan-Meier method; and ii) anatomical predictors of VTE recurrence (SVT involving the sapheno-femoral junction (i.e. ≤3 cm), SVT of the trunk of the great saphenous vein, bilateral SVT, SVT occurring in a varicose vein (i.e. C≥2 according to CEAP classification) using a Cox multivariable model adjusted for age, sex, cancer and personal history of VTE. At baseline, all patients with SVT underwent a complete bilateral swhole leg ultrasound to exclude concurrent DVT and during follow-up, all suspected VTE recurrences were confirmed/ruled out with objective tests. All recurrences were centrally adjudicated by the study’s expert committee.

Results: Among the 479 recruited patients with iSVT, 12.5% (n=60) had a thrombotic recurrence during the 3 years of follow-up. Cumulative rates of recurrence as a PE, DVT and iSVT were 1.9%, 4.8% and 5.8%, respectively. In multivariate analysis, a thrombus involving the sapheno-femoral junction at baseline independently increased the risk of VTE recurrence (HR=3.34 [1.5-7.2]). Presence of varicose veins also increased the risk but this result did not reach statistical significance (HR=1.8 [0.9 – 3.9], p=0.11).

Conclusion: In an unselected population of patients with iSVT, long-term risk of VTE recurrence is substantial. Involvement of the sapheno-femoral junction is a strong independent predictor of VTE during the subsequent 3 years. Our results suggest the need for more aggressive management and follow-up of patients with iSVT exhibiting this anatomical characteristic.

Disclosures: Galanaud: Daichi: Membership on an entity’s Board of Directors or advisory committees , Research Funding ; bayer: Membership on an entity’s Board of Directors or advisory committees , Research Funding . Sevestre: bayer: Membership on an entity’s Board of Directors or advisory committees , Research Funding ; Daichi: Membership on an entity’s Board of Directors or advisory committees , Research Funding . Pernod: pfizer: Consultancy ; leo: Consultancy ; bristol meyers: Consultancy ; Daichi: Consultancy ; bayer: Consultancy . Brisot: bayer: Membership on an entity’s Board of Directors or advisory committees ; daichi: Membership on an entity’s Board of Directors or advisory committees . Quéré: 3-M: Research Funding ; thuasne: Research Funding ; aspen: Research Funding ; daichi: Membership on an entity’s Board of Directors or advisory committees ; bayer: Membership on an entity’s Board of Directors or advisory committees ; leo: Membership on an entity’s Board of Directors or advisory committees .

*signifies non-member of ASH